血清生物标志物的作用在评估和预测内学活动在炎症性肠道疾病的作用
Xue Liu1, Lin-Xiao Pan1, Jia-Xian Pei1
1Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
World journal of gastroenterology
|June 11, 2025
概括
像C反应蛋白 (CRP) 和中性粒细胞与淋巴细胞比率 (NLR) 这样的生物标志物与炎症性肠病活动相关. 使用这些生物标志物的诺莫格拉姆模型可以预测性结肠炎 (UC) 和克罗恩病 (CD) 的疾病严重程度和治疗反应.
科学领域:
- 胃肠病学和肝病学 胃肠学和肝病学
- 临床诊断 临床诊断 临床诊断
- 生物标志物发现发现
背景情况:
- 内镜是诊断和评估炎症性肠病 (IBD) 活动的标准,但具有侵入性和成本.
- 需要可访问的,非侵入性的生物标志物来帮助IBD诊断和管理.
- 这项研究研究了各种血液生物标志物的实用性,以反映内镜疾病活动.
研究的目的:
- 确定在性结肠炎 (UC) 和克罗恩病 (CD) 中特定生物标志物和内学活性之间的相关性.
- 评估这些生物标志物的诊断意义.
- 使用已识别的生物标志物,开发内镜疾病活动的预测模型.
主要方法:
- 对365名UC患者,319名CD患者和100名对照患者的回顾性分析.
- 一组生物标志物的分析,包括完整血清参数,白蛋白,球蛋白,C反应蛋白 (CRP) 和红细胞沉率 (ESR).
- 计算生物标志物比率,如CRP/白 (CAR) 和中性粒细胞/淋巴细胞 (NLR),以与内镜检测结果相关联.
主要成果:
- 在IBD患者和对照人群之间,以及在轻度和重度疾病活动之间,观察到许多生物标志物 (例如CRP,NLR,血红蛋白) 的显著差异.
- 在UC和CD患者中,CRP,CAR和CRP/淋巴细胞 (CLR) 的基线水平升高与更好的内镜治疗反应有关.
- 开发的UC (使用ESR,CAR,血小板/白蛋白比率 [PAR]) 和CD (使用白蛋白/球蛋白比率 [AGR],PAR) 的诺莫格拉姆模型显示了内学活动的预测价值.
结论:
- 一些生物标志物,包括CRP,CAR,CLR和NLR,与UC和CD的内学活性有显著的相关性.
- 升高的CRP,CAR和CLR水平预测IBD患者治疗反应的可能性更高.
- 开发的诺莫格拉姆模型为预测内镜疾病活动提供了精确和临床适用的方法.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
323
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
323
Serum Laboratory Studies, Stool Test, Breath Test
318
Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...
318
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
96
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
96
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
Inflammatory Bowel Disease II: Crohn's Disease
200
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
200
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
119
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
119


